These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 21159061)

  • 1. Potential anti-cancer activity of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a histone deacetylase inhibitor, against breast cancer both in vitro and in vivo.
    Park KC; Kim SW; Park JH; Song EH; Yang JW; Chung HJ; Jung HJ; Suh JS; Kwon HJ; Choi SH
    Cancer Sci; 2011 Feb; 102(2):343-50. PubMed ID: 21159061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-tumor activity of N-hydroxy-7-(2-naphthylthio) heptanomide, a novel histone deacetylase inhibitor.
    Kim DH; Lee J; Kim KN; Kim HJ; Jeung HC; Chung HC; Kwon HJ
    Biochem Biophys Res Commun; 2007 Apr; 356(1):233-8. PubMed ID: 17353008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-hydroxy-7-(2-naphthylthio) heptanomide inhibits retinal and choroidal angiogenesis.
    Kim JH; Kim JH; Oh M; Yu YS; Kim KW; Kwon HJ
    Mol Pharm; 2009; 6(2):513-9. PubMed ID: 19718802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
    Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells.
    Park KC; Heo JH; Jeon JY; Choi HJ; Jo AR; Kim SW; Kwon HJ; Hong SJ; Han KS
    BMC Cancer; 2015 Jan; 15():19. PubMed ID: 25613585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential anti-cancer effect of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a novel histone deacetylase inhibitor, for the treatment of thyroid cancer.
    Kim SM; Park KC; Jeon JY; Kim BW; Kim HK; Chang HJ; Choi SH; Park CS; Chang HS
    BMC Cancer; 2015 Dec; 15():1003. PubMed ID: 26698299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
    Yin D; Ong JM; Hu J; Desmond JC; Kawamata N; Konda BM; Black KL; Koeffler HP
    Clin Cancer Res; 2007 Feb; 13(3):1045-52. PubMed ID: 17289901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.
    Munster PN; Troso-Sandoval T; Rosen N; Rifkind R; Marks PA; Richon VM
    Cancer Res; 2001 Dec; 61(23):8492-7. PubMed ID: 11731433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent in vivo anti-breast cancer activity of IN-2001, a novel inhibitor of histone deacetylase, in MMTV/c-Neu mice.
    Joung KE; Min KN; An JY; Kim DK; Kong G; Sheen YY
    Cancer Res; 2006 May; 66(10):5394-402. PubMed ID: 16707467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new histone deacetylase inhibitor improves liver fibrosis in BDL rats through suppression of hepatic stellate cells.
    Park KC; Park JH; Jeon JY; Kim SY; Kim JM; Lim CY; Lee TH; Kim HK; Lee HG; Kim SM; Kwon HJ; Suh JS; Kim SW; Choi SH
    Br J Pharmacol; 2014 Nov; 171(21):4820-30. PubMed ID: 24467283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
    Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
    Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo.
    Luong QT; O'Kelly J; Braunstein GD; Hershman JM; Koeffler HP
    Clin Cancer Res; 2006 Sep; 12(18):5570-7. PubMed ID: 17000694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities.
    Zhang Y; Feng J; Jia Y; Wang X; Zhang L; Liu C; Fang H; Xu W
    J Med Chem; 2011 Apr; 54(8):2823-38. PubMed ID: 21476600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor effects of a novel histone deacetylase inhibitor NK-HDAC-1 on breast cancer.
    Li ZH; Zhang XB; Han XQ; Feng CR; Wang FS; Wang PG; Shen J; Shi YK
    Oncol Rep; 2013 Jul; 30(1):499-505. PubMed ID: 23624828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticancer activity of SAHA, a potent histone deacetylase inhibitor, in NCI-H460 human large-cell lung carcinoma cells in vitro and in vivo.
    Zhao Y; Yu D; Wu H; Liu H; Zhou H; Gu R; Zhang R; Zhang S; Wu G
    Int J Oncol; 2014 Feb; 44(2):451-8. PubMed ID: 24297449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma.
    Dalgard CL; Van Quill KR; O'Brien JM
    Clin Cancer Res; 2008 May; 14(10):3113-23. PubMed ID: 18483379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells.
    Komatsu N; Kawamata N; Takeuchi S; Yin D; Chien W; Miller CW; Koeffler HP
    Oncol Rep; 2006 Jan; 15(1):187-91. PubMed ID: 16328054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity of SK-7041, a novel histone deacetylase inhibitor, in human lung and breast cancer cells.
    Lee KW; Kim JH; Park JH; Kim HP; Song SH; Kim SG; Kim TY; Jong HS; Jung KH; Im SA; Kim TY; Kim NK; Bang YJ
    Anticancer Res; 2006; 26(5A):3429-38. PubMed ID: 17094463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a tetrahydroisoquinoline-based hydroxamic acid derivative (ZYJ-34c) as histone deacetylase inhibitor with potent oral antitumor activities.
    Zhang Y; Fang H; Feng J; Jia Y; Wang X; Xu W
    J Med Chem; 2011 Aug; 54(15):5532-9. PubMed ID: 21714538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.
    Suzuki T; Nagano Y; Kouketsu A; Matsuura A; Maruyama S; Kurotaki M; Nakagawa H; Miyata N
    J Med Chem; 2005 Feb; 48(4):1019-32. PubMed ID: 15715470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.